In chronic myelogenous leukemia (CML), pharmacological or genetic inhibition of SIRT1 was shown to increase apoptosis in leukemia stem cells [81], which indicates that activation of p53 via SIRT1 inhibition is a feasible approach to target CML stem cells. Here, TP53 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.